CJC-1295 / Ipamorelin Blend
For Research Use Only
Injectable
A research blend pairing a GHRH analog with a selective growth-hormone secretagogue, studied for synergistic GH-axis signaling in laboratory models. Work focuses on pulsatile growth-hormone release patterns rather than exogenous hormone replacement. Laboratory research areas include: GH secretagogue pairing, pituitary signaling assays, and endocrine pulse dynamics.
Size: 5/5mg
$125.00
In stockCheckout opens once payment is connected.
Certificates of analysis
- Batch LL-QC68125394 (published 2026-06-07)
Research guides
- CJC-1295 and Ipamorelin in Animal Growth Hormone Research: What the Published Literature ReportsA research-framing overview of how CJC-1295 and ipamorelin appear in the peer-reviewed musculoskeletal literature, drawing on a PRISMA-guided scoping review that found the evidence base is dominated by preclinical animal models, with human investigations limited and methodologically heterogeneous.
- CJC-1295 and Ipamorelin in the GH–IGF-1 Axis Literature: What Published Reviews ReportA research-framing overview of how two 2026 narrative reviews characterise CJC-1295 (with and without DAC) and ipamorelin within the growth hormone–IGF-1 axis literature, including how the reviews classify the strength of human evidence, reported adverse-effect domains, product-quality uncertainty, and antidoping context.
- Ipamorelin and the Ghrelin/GHSR System: What the Published Literature CoversA research-library summary of the available cited literature linking ipamorelin to the ghrelin/growth hormone secretagogue receptor (GHSR) axis, drawn from a teleost study in black seabream that characterised the ghrelin gene and examined ghrelin transcript levels after in vivo ipamorelin administration.
This product is not for human or animal consumption. Misuse of this product is illegal.